The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations

Progress in Biophysics and Molecular Biology

Volumn 84, Issue 2-3, 2004, Pages 301-319

  Collidge, Tara A ^a   Lammie, G Alistair ^b   Fleming, Stewart ^c   Mullins, John J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Malignant hypertension; Renin angiotensin system; Stroke; Transgenic rat

Indexed keywords

ANIMALIA;

EID: 1242344043     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2003.11.003     Document Type: Review

References (100)

1. Adam A., Raij L. Nitric oxide-angiotensin II axis in renal and cardiovascular injury. J. Nephrol. 13:2000;211-220.
2. Bachmann S., Peters J., Engler E., Ganten D., Mullins J. Transgenic rats carrying the mouse renin gene - morphological characterization of a low-renin hypertension model. Kidney Int. 41:1992;24-36.
3. Bishop J.E., Kiernan L.A., Montgomery H.E., Gohlke P., McEwan J.R. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovasc. Res. 47:2000;57-67.
4. Bohlender J., Fukamizu A., Lippoldt A., Nomura T., Dietz R., Menard J., Murakami K., Luft F.C., Ganten D. High human renin hypertension in transgenic rats. Hypertension. 29:1997;428-434.
5. Bohm M., Moll M., Schmid B., Paul M., Ganten D., Castellano M., Erdmann E. Beta-adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension. 24:1994;653-662.
6. Bohm M., Lee M., Kreutz R., Kim S., Schinke M., Djavidani B., Wagner J., Kaling M., Wienen W., Bader M.et al. Angiotensin II receptor blockade in TGR(mREN2)27. effects of renin-angiotensin-system gene expression and cardiovascular functions J. Hypertens. 13:1995;891-899.
7. Brackett N.C. Jr., Koppel M., Randall R.E. Jr., Nixon W.P. Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter's syndrome). Am. J. Med. 44:1968;803-819.
8. Brasier A.R., Recinos A. III, Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 22:2002;1257-1266.
9. Bush E., Maeda N., Kuziel W.A., Dawson T.C., Wilcox J.N., DeLeon H., Taylor W.R. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension. 36:2000;360-363.
10. Byrom F. The pathogenesis of hypertensive encephalopathy and its relation to the malignant phase of hypertension. Experimental evidence from the hypertensive rat. Lancet. 2:1954;201-211.
11. Byrom F. Spasm, constriction, and hypertensive cerebral arteries. Am. Heart J. 90:1975;676-677.
12. Chiaraviglio E. Effect of renin-angiotensin system on sodium intake. J. Physiol. 255:1976;57-66.
13. Coyle P., Feng X. Risk area and infarct area relations in the hypertensive stroke-prone rat. Stroke. 24:1993;705-709. (Discussion 710).
14. Culman J., Blume A., Gohlke P., Unger T. The renin-angiotensin system in the brain. possible therapeutic implications for at(1)-receptor blockers J. Hum. Hypertens. 16(Suppl 3):2002;S64-S70.
15. Danser A.H., vanKats J.P., Admiraal P.J., Derkx F.H., Lamers J.M., Verdouw P.D., Saxena P.R., Schalekamp M.A. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 24:1994;37-48.
16. Dauda G., Mohring J., Hofbauer K.G., Homsy E., Miksche U., Orth H., Gross F. The vicious circle in acute malignant hypertension of rats. Clin. Sci. Mol. Med. 45(Suppl 1):1973;251s-255s.
17. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A. Jr., Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:1995;60-68.
18. Dickinson C.J. Why are strokes related to hypertension? Classic studies and hypotheses revisited. J. Hypertens. 19:2001;1515-1521.
19. Dickinson C.J., Thomson A.D. A post mortem study of the main cerebral arteries with special reference to their possible role in blood pressure regulation. Clin. Sci. 19:1960;513-538.
20. DiNicolantonio R., Hutchinson J.S., Mendelsohn F.A. Exaggerated salt appetite of spontaneously hypertensive rats is decreased by central angiotensin-converting enzyme blockade. Nature. 298:1982;846-848.
21. Dubey R.K., Jackson E.K., Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J. Clin. Invest. 96:1995;141-149.
22. Dzau V.J. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease. a unifying hypothesis Hypertension. 37:2001;1047-1052.
23. Engler S., Paul M., Pinto Y.M. The TGR(mRen2)27 transgenic rat model of hypertension. Regul. Pept. 77:1998;3-8.
24. Fisher C.M. The arterial lesions underlying lacunes. Acta Neuropathol. (Berlin). 12:1968;1-15.
25. Fisher C.M. Lacunar strokes and infarcts. a review Neurology. 32:1982;871-876.
26. Fitts D.A., Starbuck E.M., Ruhf A. Circumventricular organs and ANG II-induced salt appetite. blood pressure and connectivity Am. J. Physiol. Regul. Integr. Comp. Physiol. 279:2000;R2277-R2286.
27. Fitts D.A., Thunhorst R.L. Rapid elicitation of salt appetite by an intravenous infusion of angiotensin II in rats. Am. J. Physiol. 270:1996;R1092-R1098.
28. Fitzsimons J.T. Angiotensin, thirst, and sodium appetite. Physiol. Rev. 78:1998;583-686.
29. Fleming S. Malignant hypertension - the role of the paracrine renin-angiotensin system. J. Pathol. 192:2000;135-139.
30. Gavras H., Brunner H.R., Laragh J.H., Vaughan E.D. Jr., Koss M., Cote L.J., Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. role of renin and sodium in vascular changes Circ. Res. 36:1975;300-309.
31. Giachelli C., Bae N., Lombardi D., Majesky M., Schwartz S. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem. Biophys. Res. Commun. 177:1991;867-873.
32. Gibbons G.H. The pathophysiology of hypertension. the importance of angiotensin II in cardiovascular remodeling Am. J. Hypertens. 11:1998;177S-181S.
33. Giese J. Renin, angiotensin and hypertensive vascular damage. a review Am. J. Med. 55:1973;315-332.
34. Grafe M., Auch-Schwelk W., Zakrzewicz A., Regitz-Zagrosek V., Bartsch P., Graf K., Loebe M., Gaehtgens P., Fleck E. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ. Res. 81:1997;804-811.
35. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1994;1141-1148.
36. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100:1997;2153-2157.
37. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 377:1995;744-747.
38. Hirsch A.T., Talsness C.E., Schunkert H., Paul M., Dzau V.J. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ. Res. 69:1991;475-482.
39. Ichiki T., Labosky P.A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B.L., Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 377:1995;748-750.
40. Inada Y., Wada T., Ojima M., Sanada T., Shibouta Y., Kanagawa R., Ishimura Y., Fujisawa Y., Nishikawa K. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 19:1997;1079-1099.
41. Johansson B.B. Cerebral vascular bed in hypertension and consequences for the brain. Hypertension. 6:1984;III81-III86.
42. Kantachuvesiri S., Fleming S., Peters J., Peters B., Brooker G., Lammie A.G., McGrath I., Kotelevtsev Y., Mullins J.J. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J. Biol. Chem. 276:2001;36727-36733.
43. Kantachuvesiri S., Haley C.S., Fleming S., Kurian K., Whitworth C.E., Wenham P., Kotelevtsev Y., Mullins J.J. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int. 56:1999;414-420.
44. Kobayashi N., Hara K., Higashi T., Matsuoka H. Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats. Am. J. Hypertens. 13:2000;1088-1096.
45. Kobayashi N., Hara K., Watanabe S., Higashi T., Matsuoka H. Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Am. J. Hypertens. 13:2000;199-207.
46. Lammie G.A. Hypertensive cerebral small vessel disease and stroke. Brain Pathol. 12:2002;358-370.
47. Lassen N.A., Agnoli A. The upper limit of autoregulation of cerebral blood flow - on the pathogenesis of hypertensive encepholopathy. Scand. J. Clin. Lab. Invest. 30:1972;113-116.
48. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., Harrison D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 95:1997;588-593.
49. Lee M.A., Bohm M., Kim S., Bachmann S., Bachmann J., Bader M., Ganten D. Differential gene expression of renin and angiotensinogen in the TGR(mREN-2)27 transgenic rat. Hypertension. 25:1995;570-580.
50. Lee M.A., Bohm M., Paul M., Bader M., Ganten U., Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am. J. Physiol. 270:1996;E919-E929.
51. Lee R.M. Morphology of cerebral arteries. Pharmacol. Ther. 66:1995;149-173.
52. Liaw L., Almeida M., Hart C.E., Schwartz S.M., Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74:1994;214-224.
53. Lip G.Y., Beevers M., Beevers G. The failure of malignant hypertension to decline. a survey of 24 years' experience in a multiracial population in England J. Hypertens. 12:1994;1297-1305.
54. Madrid M.I., Garcia-Salom M., Tornel J., DeGasparo M., Fenoy F.J. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 273:1997;R1676-R1682.
55. Margolis G., Sadowsky C.H. Letter. how does blood-pressure cause stroke? Lancet. 1:1976;538.
56. Mervaala E.M.A., Muller D.N., Park J.-K., Schmidt F., Lohn M., Breu V., Dragun D., Ganten D., Haller H., Luft F.C. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 33:1999;389-395.
57. Mervaala E., Muller D.N., Park J.-K., Dechend R., Schmidt F., Fiebeler A., Bieringer M., Breu V., Ganten D., Haller H., Luft F.C. Cyclosporin a protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension. 35:2000;360-366.
58. Mohring J., Petri M., Szokol M., Haack D., Mohring B. Effects of saline drinking on malignant course of renal hypertension in rats. Am. J. Physiol. 230:1976;849-857.
59. Montgomery H.E., Kiernan L.A., Whitworth C.E., Fleming S., Unger T., Gohlke P., Mullins J.J., McEwan J.R. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J. Hypertens. 16:1998;635-643.
60. Muller D.N., Dechend R., Mervaala E.M., Park J.K., Schmidt F., Fiebeler A., Theuer J., Breu V., Ganten D., Haller H., Luft F.C. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 35:2000;193-201.
61. Muller D.N., Mervaala E.M.A., Schmidt F., Park J.-K., Dechend R., Genersch E., Breu V., Loffler B.-M., Ganten D., Schneider W., Haller H., Luft F.C. Effect of bosentan on NF-{kappa}B, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 36:2000;282-290.
62. Mullins J.J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 344:1990;541-544.
63. Munzenmaier D.H., Greene A.S. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 27:1996;760-765.
64. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc. Natl Acad. Sci. USA. 88:1991;10045-10048.
65. Nora E.H., Munzenmaier D.H., Hansen-Smith F.M., Lombard J.H., Greene A.S. Localization of the ANG II type 2†receptor in the microcirculation of skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 275:1998;H1395-H1403.
66. Okamoto, K., Yamori, Y., Nagaoka, A., 1974. Establishment of the stroke-prone spontaneously hypertensive rat. Circ. Res. 34(Suppl. 1), I-143-I-153.
67. Palomaki J.F., Lindheimer M.D. Sodium depletion simulating deterioration in a toxemic pregnancy. N. Engl. J. Med. 282:1970;88-89.
68. Pasternack A., Perheentupa J. Hypertensive angiopathy in familial chloride diarrhea. Lancet. 2:1966;1047-1049.
69. Pasternack A., Perheentupa J., Launiala K., Hallman N. Kidney biopsy findings in familial chloride diarrhoea. Acta Endocrinol. (Copenhagen). 55:1967;1-9.
70. Peng H.B., Libby P., Liao J.K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem. 270:1995;14214-14219.
71. Peters J., Farrenkopf R., Clausmeyer S., Zimmer J., Kantachuvesiri S., Sharp M.G., Mullins J.J. Functional significance of prorenin internalization in the rat heart. Circ. Res. 90:2002;1135-1141.
72. Prescott G., Silversides D.W., Chiu S.M., Reudelhuber T.L. Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. Physiol. Genomics. 4:2000;67-73.
73. PROGRESS Management Committee. 1996. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. Perindopril Protection against Recurrent Stroke Study. J. Hypertens. 14 (Suppl), S41-S45 (discussion S45-S46).
74. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20:2000;645-651.
75. Robinson M. Salt in pregnancy. Lancet. 1:1958;178-181.
76. Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Suzuki Y., Mezzano S., Plaza J.J., Egido J. Role of the renin-angiotensin system in vascular diseases. expanding the field Hypertension. 38:2001;1382-1387.
77. Ruiz-Ortega M., Lorenzo O., Suzuki Y., Ruperez M., Egido J. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10:2001;321-329.
78. Ruiz-Ortega M., Ruperez M., Esteban V., Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr. Hypertens. Rep. 5:2003;73-79.
79. Sadoshima J., Xu Y., Slayter H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:1993;977-984.
80. Saris J.J., Derkx F.H., DeBruin R.J., Dekkers D.H., Lamers J.M., Saxena P.R., Schalekamp M.A., JanDanser A.H. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am. J. Physiol. Heart Circ. Physiol. 280:2001;H1706-H1715.
81. Scheuer D.A., Perrone M.H. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 264:1993;R917-R923.
82. Springate J.E., Feld L.G., Ganten D. Renal function in hypertensive rats transgenic for mouse renin gene. Am. J. Physiol. 266:1994;F731-F737.
83. Studer R., Reinecke H., Muller B., Holtz J., Just H., Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J. Clin. Invest. 94:1994;301-310.
84. Su E.J., Lombardi D.M., Siegal J., Schwartz S.M. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension. 31:1998;1331-1337.
85. Sutherland L.E., Hartroft P., Balis J.U., Bailey J.D., Lynch M.J. Bartter's syndrome. A report of four cases including three in one sibship, with comparative histologic evaluation of the juxtaglomerular apparatuses and glomeruli. Acta Paediatr. Scand. 201(Suppl 201):1970;1.
86. Tawfik-Schlieper H., Moll M., Schmid B., Schwinger R.H., Paul M., Ganten D., Bohm M. Alterations of cardiac alpha- and beta-adrenoceptors and inotropic responsiveness in hypertensive transgenic rats harbouring the mouse renin gene (TGR(mREN2)27). Clin. Exp. Hypertens. 17:1995;631-648.
87. Thybo N.K., Korsgaard N., Mulvany M.J. Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J. Hypertens. 10:1992;1191-1196.
88. Tsuchida S., Matsusaka T., Chen X., Okubo S., Niimura F., Nishimura H., Fogo A., Utsunomiya H., Inagami T., Ichikawa I. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J. Clin. Invest. 101:1998;755-760.
89. Tsutsumi Y., Matsubara H., Masaki H., Kurihara H., Murasawa S., Takai S., Miyazaki M., Nozawa Y., Ozono R., Nakagawa K., Miwa T., Kawada N., Mori Y., Shibasaki Y., Tanaka Y., Fujiyama S., Koyama Y., Fujiyama A., Takahashi H., Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 104:1999;925-935.
90. Tummala P.E., Chen X.L., Sundell C.L., Laursen J.B., Hammes C.P., Alexander R.W., Harrison D.G., Medford R.M. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. a potential link between the renin-angiotensin system and atherosclerosis Circulation. 100:1999;1223-1229.
91. Ushio-Fukai M., Zafari A.M., Fukui T., Ishizaka N., Griendling K.K. P22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 271:1996;23317-23321.
92. van Kesteren C.A., Danser A.H., Derkx F.H., Dekkers D.H., Lamers J.M., Saxena P.R., Schalekamp M.A. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension. 30:1997;1389-1396.
93. Veerasingham S.J., Raizada M.K. Brain renin-angiotensin system dysfunction in hypertension. recent advances and perspectives Br. J. Pharmacol. 139:2003;191-202.
94. Veniant M., Menard J., Bruneval P., Morley S., Gonzales M.F., Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. 98:1996;1966-1970.
95. Whitworth C.E., Fleming S., Kotelevtsev Y., Manson L., Brooker G.A., Cumming A.D., Mullins J.J. A genetic model of malignant phase hypertension in rats. Kidney Int. 47:1995;529-535.
96. Wiener J., Lombardi D.M., Su J.E., Schwartz S.M. Immunohistochemical and molecular characterization of the differential response of the rat mesenteric microvasculature to angiotensin-II infusion. J. Vasc. Res. 33:1996;195-208.
97. Wu J., Edwards D., Berecek K. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension. 23:1994;819-822.
98. Yamauchi T., Nagahama M., Watanabe T., Ishizuka Y., Hori H., Murakami K. Site-directed mutagenesis of human prorenin. Substitution of three arginine residues in the propeptide with glutamine residues yields active prorenin. J. Biochem. (Tokyo). 107:1990;27-31.
99. Yamori Y., Horie R. Developmental course of hypertension and regional cerebral blood flow in stroke-prone spontaneously hypertensive rats. Stroke. 8:1977;456-461.
100. Zarifis J., Lip G.Y., Leatherdale B., Beevers G. Malignant hypertension in association with primary aldosteronism. Blood Press. 5:1996;250-254.